Sugi Predict

Sugi Predict / Compounds / SCHEMBL3596576

SCHEMBL3596576

SCHEMBL3596576

CCOC(=O)CNc1ccc(C(=O)c2c(C)c(OC)c3ccccn23)cc1OC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 4/20 0.46
▸ NPC1 O15118 2/20 0.46
▸ ATM Q13315 2/20 0.46
▸ RXFP1 Q9HBX9 1/20 0.46
▸ MAPT P10636 7/20 0.42
▸ ALDH1A1 P00352 9/20 0.41
▸ LMNA P02545 4/20 0.41
▸ KDM4E B2RXH2 4/20 0.41
▸ FNTA P49354 1/20 0.41
▸ FNTB P49356 1/20 0.41
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ HPGD P15428 2/20 0.37
▸ SIRT3 Q9NTG7 1/20 0.37
▸ SIRT5 Q9NXA8 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ HTT P42858 3/20 0.37
▸ GLA P06280 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3595364 0.90 NPC1 (0.46) GAANPC1ATMRXFP1MAPT
SCHEMBL3593704 0.89 GAA (0.41) GAANPC1ATMRXFP1MAPT
SCHEMBL3601464 0.87 MAPT (0.47) GAANPC1ATMRXFP1MAPT
SCHEMBL6217961 0.83 NPC1 (0.46) GAANPC1ATMRXFP1MAPT
Hydrochloric Acid SCHEMBL3611393 0.83 NPC1 (0.46) GAANPC1ATMRXFP1MAPT
SCHEMBL3606724 0.82 NPC1 (0.46) GAANPC1ATMRXFP1MAPT
SCHEMBL3610782 0.81 NPC1 (0.44) GAANPC1ATMRXFP1MAPT
Hydrochloric Acid SCHEMBL3602933 0.81 NPC1 (0.40) GAANPC1ATMRXFP1MAPT
SCHEMBL3602590 0.79 NPC1 (0.40) GAANPC1ATMRXFP1MAPT
SCHEMBL2519397 0.78 NPC1 (0.46) GAANPC1ATMRXFP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7803811-B2 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, method for preparing them and pharmaceutical compositions containing them SANOFI-AVENTIS (FR) 2010-09-28 — — US disclosed
US-20090023770-A1 Novel 1,2,3-Substituted Indolizine Derivatives, Inhibitors of FGFs, Method for Preparing Them and Pharmaceutical Compositions Containing Them SANOFI-AVENTIS (FR) 2009-01-22 — — US disclosed
US-7442708-B2 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same SANOFI-AVENTIS (FR) 2008-10-28 — — US disclosed
US-20050203126-A1 Novel 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same SANOFI (FR) 2005-09-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203126-A1 Novel 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same FGFR3, FGFR1, NTRK3 GAA 4090/4885NPC1 2040/4885ATM 3197/4885
US-20090023770-A1 Novel 1,2,3-Substituted Indolizine Derivatives, Inhibitors of FGFs, Method for Preparing Them and Pharmaceutical Compositions Containing Them FGF2, FGF1, FGFR1 GAA 2443/4885NPC1 2760/4885ATM 3401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.